Tibet Rhodiola Pharmaceutical Holding Co

Chengdu University of TCM Yin Hai Eye Hospital has seen its owners’ equity turn negative due to persistent losses, reducing shareholder Taiji Group’s investment book value to zero. Taiji Group’s 2025 annual report shows the investment cost in this associate was 53.99 million yuan, with a year-end book value of zero yuan, as cumulative losses exceeded the initial investment cost. Another shareholder, Tibet Pharmaceutical, disclosed in its 2025 annual report that cumulative unrecognised losses for the hospital amounted to 12.05 million yuan. It invested 32.996 million yuan for a 9.57 percent stake in 2016, and its financial reports over the years have also reflected years of losses. The hospital was established in 2016 as a tertiary-level eye hospital, led by Professor Duan Junguo of Chengdu University of Traditional Chinese Medicine, together with social capital including Taiji Group, Tibet Pharmaceutical, and Guizhou Bailing. However, it has been loss-making since its inception, and recently has experienced situations such as suspension of outpatient services, a deadline to vacate the premises, and wage arrears.